AU2001286727A1 - Prodrugs activated by plasmin and their use in cancer chemotherapy - Google Patents

Prodrugs activated by plasmin and their use in cancer chemotherapy

Info

Publication number
AU2001286727A1
AU2001286727A1 AU2001286727A AU8672701A AU2001286727A1 AU 2001286727 A1 AU2001286727 A1 AU 2001286727A1 AU 2001286727 A AU2001286727 A AU 2001286727A AU 8672701 A AU8672701 A AU 8672701A AU 2001286727 A1 AU2001286727 A1 AU 2001286727A1
Authority
AU
Australia
Prior art keywords
plasmin
cancer chemotherapy
prodrugs activated
prodrugs
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286727A
Inventor
Vincent Dubois
Alexandre Passioukov
Andre Trouet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coulter Pharmaceutical Inc
Original Assignee
Coulter Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coulter Pharmaceutical Inc filed Critical Coulter Pharmaceutical Inc
Publication of AU2001286727A1 publication Critical patent/AU2001286727A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
AU2001286727A 2000-08-24 2001-08-23 Prodrugs activated by plasmin and their use in cancer chemotherapy Abandoned AU2001286727A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22768600P 2000-08-24 2000-08-24
US60227686 2000-08-24
PCT/US2001/026476 WO2002015700A1 (en) 2000-08-24 2001-08-23 Prodrugs activated by plasmin and their use in cancer chemotherapy

Publications (1)

Publication Number Publication Date
AU2001286727A1 true AU2001286727A1 (en) 2002-03-04

Family

ID=22854074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286727A Abandoned AU2001286727A1 (en) 2000-08-24 2001-08-23 Prodrugs activated by plasmin and their use in cancer chemotherapy

Country Status (3)

Country Link
US (2) US7402556B2 (en)
AU (1) AU2001286727A1 (en)
WO (1) WO2002015700A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355675A1 (en) * 2001-01-30 2003-10-29 Universite Catholique De Louvain Anti-tumor compounds
US7129261B2 (en) 2001-05-31 2006-10-31 Medarex, Inc. Cytotoxic agents
WO2004005309A2 (en) 2002-07-08 2004-01-15 Pliva - Istrazivacki Institut D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
ATE429441T1 (en) * 2002-07-08 2009-05-15 Glaxosmithkline Zagreb HYBRID MOLECULES OF MACROLIDS WITH STEROIDAL/NON-STEROIDAL ANTI-INFLAMMATORY ACTIVE MOLECULES
FR2847268B1 (en) * 2002-11-19 2006-09-29 Coletica METHOD FOR IDENTIFYING AN EVENTUALLY MODIFICATION OF AT LEAST ONE BIOLOGICAL PARAMETER USING LIVING CELLS SUBJECT TO STRESS AND LIVING CELLS NOT SUBJECT TO THIS SAME STRESS
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
JP2010519310A (en) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド Chemical linker having a single amino acid and complex thereof
NO2842575T3 (en) 2008-03-18 2018-02-24
CA2722858C (en) 2008-04-30 2017-08-29 Siemens Medical Solutions Usa, Inc. Substrate based pet imaging agents
US9238878B2 (en) * 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
EP2677029B1 (en) * 2011-05-19 2017-05-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
WO2012162175A1 (en) 2011-05-20 2012-11-29 Howard University Emetine derivatives, prodrugs containing same, and methods of treating conditions using same
KR102083371B1 (en) 2012-11-21 2020-03-04 입센 바이오이노베이션 리미티드 Methods for the manufacture of proteolytically processed polypeptides
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014160037A2 (en) 2013-03-14 2014-10-02 The Regents Of The University Of California Activatable membrane-interacting peptides and methods of use
CN105764501A (en) 2013-07-26 2016-07-13 现代化制药公司 Compositions to improve the therapeutic benefit of bisantrene
EA036949B1 (en) 2015-05-29 2021-01-19 Эрроухэд Фармасьютикалз, Инк. Biologically cleavable tetrapeptide linking agents
CN109071634A (en) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 Antibody coupling matter and its preparation and application
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US10287291B2 (en) 2016-08-19 2019-05-14 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
USRE49961E1 (en) * 2016-10-21 2024-05-07 Cem Corporation Solid phase peptide syntheses
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
DE2936543A1 (en) * 1979-09-10 1981-04-09 Behringwerke Ag, 3550 Marburg CHROMOGENIC COMPOUNDS
AU598750B2 (en) * 1985-09-27 1990-07-05 Mitsubishi Chemical Corporation Phenylalanine derivative and proteinase inhibitor
WO1996005863A1 (en) * 1994-08-19 1996-02-29 La Region Wallonne Compounds, pharmaceutical composition and diagnostic device comprising same and their use
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
NZ512171A (en) 1998-12-11 2004-07-30 Medarex Inc Prodrug compound comprising a therapeutic agent, an oligopeptide with a non-genetically encoded amino acid, a stabilizing group and optionally a linker group
WO2002061049A2 (en) * 2001-01-31 2002-08-08 Millennium Pharmaceuticals, Inc. Novel molecules of the pyrin/nbs/lrr protein family and uses thereof

Also Published As

Publication number Publication date
US20090076176A1 (en) 2009-03-19
US7402556B2 (en) 2008-07-22
US20040171562A1 (en) 2004-09-02
WO2002015700A1 (en) 2002-02-28
US7893023B2 (en) 2011-02-22

Similar Documents

Publication Publication Date Title
AU2001286727A1 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
AU2001253140A1 (en) Tumor markers in ovarian cancer
AU3084901A (en) Volume holographic diffusers
MXPA03004644A (en) Phenylacetamido- pyrazole derivatives and their use as antitumor agents.
AU2003293376A1 (en) Anti-angiogenic compounds and their use in cancer treatment
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU2001227122A1 (en) Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
AUPQ926600A0 (en) Improvements in fluid delivery systems
GB0002835D0 (en) Drug resistance in cancer
AU2003217421A1 (en) Prostate specific genes and the use thereof in design or therapeutics
AU2001261750A1 (en) Laminate and its use
AU2002362613A1 (en) Galectins-1-and-4 in tumor development
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001258098A1 (en) Ginsenoside chemotherapy
AU2001272655A1 (en) Improvements in valves
AUPQ526100A0 (en) Improvements in single use syringes
GB0028879D0 (en) Adsorbents and their use
AU2001257325A1 (en) Cancer treatment
AU2001268466A1 (en) 55p4h4: gene expressed in various cancers
AU2002223468A1 (en) Dual shower in three designs
IL150702A0 (en) Improvements in transceivers
AU2001257168A1 (en) Cancer treatment
AU2001269579A1 (en) Ornamental display utilizing particles circulating in the display
AU2001247922A1 (en) Calpain inhibitors in cancer treatment